Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
24
×
Tags
boston blog main
24
×
drugs
24
×
life sciences
national blog main
boston top stories
clinical trials
national top stories
new york blog main
new york top stories
biotech
fda
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
texas top stories
boston
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
wisconsin blog main
wisconsin top stories
indiana blog main
indiana top stories
national
cancer
pfizer
startups
alnylam pharmaceuticals
gene therapy
celgene
deals
eli lilly
investing
What
drug
fda
medicine
new
alnylam
medical
rna
ago
approved
bio
pharmaceuticals
roundup
big
companies
data
disease
interference
known
life
long
make
medicines
oks
rnai
second
week
american
annual
approval
ash
biotech
biotechs
blood
cells
conference
crispr
decades
diego
drugs
europe
Language
unset
unknown
Current search:
drugs
×
photo
×
" boston blog main "
×
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
Nobel Prize in Medicine Goes to 3 Who Showed How Cells Sense Oxygen Levels
@xconomy.com
4 years ago
Drug Pricing: Innovation, Investment, and the Public Good
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
4 years ago
PanTheryx Lands $50M to Use “First Milk” to Target Gut Microbiome
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
4 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
JLabs’ Luby Takes the Reins at TMC Innovation Institute in Houston
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision